Literature DB >> 8556519

Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.

C Osiowy1, D Horne, R Anderson.   

Abstract

Respiratory syncytial virus (RSV) convalescent-phase sera and control sera from both infants ( < 6 months) and older individuals (1.5 to 90 years) were assayed for RSV-specific antibodies by neutralization, in vitro enhancing activity, and immunoprecipitation. Enhancement of RSV infection in U937 cells was demonstrated with convalescent-phase sera and was shown to be dependent on Fc receptors by blocking with human immunoglobulin G (P < 0.01). Convalescent-phase sera from infants enhanced infection at concentrations closer to physiological ones (10(-1) to 10(-3) dilutions of serum), while convalescent-phase sera from older individuals enhanced infection only at much lower concentrations (10(-3) to 10(-6) dilutions of serum; P < 0.01). To our knowledge, this is the first report of RSV-enhancing antibody activity in the sera of infants. The observed enhancing activity and the low neutralizing antibody levels are confined mostly to convalescent-phase sera from infants aged 0 to 6 months, suggesting that these factors may contribute to the increased severity of RSV disease frequently encountered in young infants.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556519      PMCID: PMC368388          DOI: 10.1128/cdli.1.6.670-677.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  48 in total

1.  Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life.

Authors:  C J Holberg; A L Wright; F D Martinez; C G Ray; L M Taussig; M D Lebowitz
Journal:  Am J Epidemiol       Date:  1991-06-01       Impact factor: 4.897

2.  Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors.

Authors:  B J Mady; D V Erbe; I Kurane; M W Fanger; F A Ennis
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

3.  Respiratory syncytial virus infection of human primary nasal and bronchial epithelial cell cultures and bronchoalveolar macrophages.

Authors:  S Becker; J Soukup; J R Yankaskas
Journal:  Am J Respir Cell Mol Biol       Date:  1992-04       Impact factor: 6.914

4.  Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients.

Authors:  J R Panuska; M I Hertz; H Taraf; A Villani; N M Cirino
Journal:  Am Rev Respir Dis       Date:  1992-04

5.  Immunity to and frequency of reinfection with respiratory syncytial virus.

Authors:  C B Hall; E E Walsh; C E Long; K C Schnabel
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

6.  Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody.

Authors:  H Ochiai; M Kurokawa; S Matsui; T Yamamoto; Y Kuroki; C Kishimoto; K Shiraki
Journal:  J Med Virol       Date:  1992-03       Impact factor: 2.327

7.  Antibody-dependent enhancement of hantavirus infection in macrophage cell lines.

Authors:  J S Yao; H Kariwa; I Takashima; K Yoshimatsu; J Arikawa; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages.

Authors:  S Becker; J Quay; J Soukup
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

9.  Effect of macrophages and in vitro infection with parainfluenza type 3 and respiratory syncytial viruses on the mitogenic response of bovine lymphocytes.

Authors:  B M Adair; H E Bradford; D P Mackie; M S McNulty
Journal:  Am J Vet Res       Date:  1992-02       Impact factor: 1.156

10.  A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies.

Authors:  T Hohdatsu; M Nakamura; Y Ishizuka; H Yamada; H Koyama
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

View more
  12 in total

Review 1.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

2.  Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.

Authors:  R Anderson; S Wang; C Osiowy; A C Issekutz
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

3.  Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.

Authors:  H B Gimenez; S Chisholm; J Dornan; P Cash
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

4.  Prevalence of antibodies against HEp-2 cell antigen in infants and children hospitalized with respiratory syncytial virus infection.

Authors:  J Forster; O Maier; J Löbbert; K Kaufmehl; H J Streckert; H Werchau
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 5.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

Review 6.  Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.

Authors:  Jop Jans; Marloes Vissers; Jacco G M Heldens; Marien I de Jonge; Ofer Levy; Gerben Ferwerda
Journal:  Rev Med Virol       Date:  2013-11-14       Impact factor: 6.989

7.  Label-free quantitative proteomics reveals regulation of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) and 5'-3'-exoribonuclease 2 (XRN2) during respiratory syncytial virus infection.

Authors:  Nicola Ternette; Cynthia Wright; Holger B Kramer; Mikael Altun; Benedikt M Kessler
Journal:  Virol J       Date:  2011-09-20       Impact factor: 4.099

8.  In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.

Authors:  Elisabeth A van Erp; Puck B van Kasteren; Teun Guichelaar; Inge M L Ahout; Cornelis A M de Haan; Willem Luytjes; Gerben Ferwerda; Oliver Wicht
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

Review 9.  Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus.

Authors:  M S Boukhvalova; K C Yim; Jcg Blanco
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

10.  Respiratory Syncytial Virus Infects Primary Neonatal and Adult Natural Killer Cells and Affects Their Antiviral Effector Function.

Authors:  Elisabeth A van Erp; Dorien Feyaerts; Maxime Duijst; H Lie Mulder; Oliver Wicht; Willem Luytjes; Gerben Ferwerda; Puck B van Kasteren
Journal:  J Infect Dis       Date:  2019-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.